User profiles for Andrew J. Pollard
 | Professor Sir Andrew PollardUniversity of Oxford Verified email at paediatrics.ox.ac.uk Cited by 59455 |
[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …
…, AVS Hill, T Lambe, SC Gilbert, AJ Pollard… - The Lancet, 2021 - thelancet.com
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …
was announced, containing far more mutations in Spike (S) than previously reported …
[HTML][HTML] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled …
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
…, AJ Pollard, M Aban, KWM Abeyskera, J Aboagye… - The Lancet, 2021 - thelancet.com
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
[HTML][HTML] Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
…, J Vekemans, TL Villafana, T Lambe, AJ Pollard… - Nature medicine, 2021 - nature.com
The global supply of COVID-19 vaccines remains limited. An understanding of the immune
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …
[HTML][HTML] Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant
…, TL Villafana, S Gilbert, AJ Pollard… - … England Journal of …, 2021 - Mass Medical Soc
Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …
[HTML][HTML] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind …
Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …
death if they develop COVID-19 and are therefore a priority for immunisation should an …
[HTML][HTML] Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that
protect against severe disease and preferably drive herd immunity. Regulators in numerous …
protect against severe disease and preferably drive herd immunity. Regulators in numerous …
[PDF][PDF] Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum
The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA.1 …
rapidly to become globally dominant and has split into a number of sublineages. BA.1 …
[HTML][HTML] Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera
The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
began when the first sequence was published, and this forms the basis for …
began when the first sequence was published, and this forms the basis for …